Presentation is loading. Please wait.

Presentation is loading. Please wait.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Published byGwendolyn Willis Modified over 6 years ago

Similar presentations

Presentation on theme: "Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment."— Presentation transcript:

1 Table 6 The results of virus isolation tests before and after oseltamivir therapy.
From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4): doi: /505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

2 Table 1 Characteristics of patients in a comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4): doi: /505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

3 Table 5 Duration of fever for influenza A and influenza B, by patient age.
From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4): doi: /505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

4 Table 4 Duration of fever after administration of the first dose of oseltamivir for influenza A or influenza B, by patient age. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4): doi: /505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

5 Table 3 Duration of fever for patients with influenza A and those with influenza B, by time to the first administration of oseltamivir after the onset of fever. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4): doi: /505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

6 Table 2 Duration of fever after administration of the first dose of oseltamivir for patients with influenza A or influenza B, by time to administration of the first dose after the onset of fever. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4): doi: /505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Download ppt "Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment."

Similar presentations

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Statement—Recommendations for Prevention and Control of Influenza in Children,

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Statement—Recommendations for Prevention and Control of Influenza in Children,
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Figure 1 Overview of Markov model for infected total hip arthroplasty

Figure 1 Overview of Markov model for infected total hip arthroplasty
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.
Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.

Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.
Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.
Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Similar presentations

Ads by Google